Biotherapies in large vessel vasculitis

G. Pazzola, F. Muratore, N. Pipitone, C. Salvarani

Research output: Contribution to journalArticlepeer-review


The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

Original languageEnglish
Pages (from-to)274-278
Number of pages5
JournalRevue de Medecine Interne
Issue number4
Publication statusPublished - Apr 1 2016


  • Biological therapies
  • Biotherapies
  • Giant cell arteritis
  • Large vessel vasculitis
  • Takayasu arteritis

ASJC Scopus subject areas

  • Gastroenterology
  • Internal Medicine


Dive into the research topics of 'Biotherapies in large vessel vasculitis'. Together they form a unique fingerprint.

Cite this